Pfizer mulls spin-off or sale of consumer health unit: sources
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
US drugmaker Pfizer Inc is evaluating a potential sale or spin-off of its consumer health division that could value the unit at as much as US$14 billion, people familiar with the matter said on Wednesday.
A Pfizer exit from the consumer health business, which includes lip balm Chapstick and painkiller Advil, would be one of its biggest corporate moves since abandoning a US$160 billion deal to buy Irish drugmaker Allergan Inc earlier this year.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
